Human placental collagen compositions, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-9770488-B2
Application number	US-201313777391-A
Country	US
Kind code	B2
Filing date	Feb 26, 2013
Priority date	Oct 6, 2006
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.

First claim

What is claimed is:

1. A method of treating a wound comprising contacting the wound with a composition comprising human placental extracellular matrix, wherein said human placental extracellular matrix comprises: (i) placental collagen that comprises between 74% and 90% Type I collagen, between 4% to 6% Type III collagen, and between 2% to 15% type IV collagen, (ii) no detectable amounts of fibronectin or laminin, and (iii) additional extracellular matrix components selected from the following groups:
(a) 4.7% elastin by dry weight and 0.28% glycosaminoglycans by dry weight;
(b) 3.2% elastin by dry weight and 0.34% glycosaminoglycans by dry weight;
(c) 4.4% elastin by dry weight and 0.38% glycosaminoglycans by dry weight; and
(d) 3.5% elastin by dry weight and 0.59% glycosaminoglycans by dry weight.

2. The method of claim 1 , wherein said composition is used as a wound filler.

3. The method of claim 1 , wherein said composition is applied directly to the site of the wound.

4. The method of claim 1 , wherein said composition is shaped to fit the site of the wound.

5. The method of claim 1 , wherein said wound is a pressure ulcer, venous ulcer, diabetic ulcer, chronic vascular ulcer, tunneled wound, undermined wound, surgical wound, trauma wound, or draining wound.

6. The method of claim 1 , wherein said wound is a leg ulcer.

7. The method of claim 6 , wherein said leg ulcer is a venous leg ulcer, an arterial leg ulcer, a diabetic leg ulcer or a decubitus leg ulcer.

8. The method of claim 1 , wherein said wound is a burn wound.

9. The method of claim 1 , wherein said composition comprises an additional pharmacologically active agent.

10. The method of claim 9 , wherein said additional pharmacologically active agent is platelet-derived growth factor, insulin-like growth factor, epidermal growth factor, transforming growth factor beta, an angiogenesis factor, an antibiotic, an antifungal agent, a hormone, an enzyme, or an enzyme inhibitor.

11. The method of claim 1 , wherein the composition further comprises placental stem cells that are allogeneic to the subject.

12. The method of claim 1 , wherein the composition further comprises placental stem cells that are autologous to the subject.

Assignees

• Anthrogenesis Corp

Inventors

• Bhatia Mohit
• Lugo Chris
• Ye Qian
• Edinger James W

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• C07K14/78 Primary

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• A61K2800/92

  Oral administration · CPC title

• A61K38/39 Primary

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title